Skyepharma appoints Andrew Derodra as Chief Financial Officer

Skyepharma appoints Andrew Derodra as Chief Financial Officer

LONDON, ENGLAND, 22 August 2013 - Skyepharma PLC (LSE: SKP), the expert oral and inhalation drug delivery company, today announces that Andrew Derodra has been appointed Chief Financial Officer and an Executive Director.  Mr Derodra is expected to join in the fourth quarter of 2013.  

 
Mr Derodra, 46, joins Skyepharma from Tate & Lyle, where he has been Group Vice President Finance & Control since 2011.  He has spent 23 years working in senior finance roles within five FTSE100 groups including SABMiller, Diageo, British Airways and Reed Elsevier. 
 
Peter Grant, CEO of Skyepharma, commented:
"This is an excellent appointment for Skyepharma and Andrew joins the Company at an important point in our development.  Andrew brings a broad range of business experience and I look forward to working with him as we leverage our strong platform for future growth and continue to create value for our shareholders."
 
Commenting on his appointment, Mr Derodra said:
"I am delighted to be joining Skyepharma at this key stage in the Group's development.  I look forward to working with the management team and with colleagues across the organisation, to help achieve the full potential of the business."
 
The Group's previous Chief Financial Officer, Peter Grant, was appointed Chief Executive Officer in January 2012 and retained responsibility for the Group's financial affairs.  As previously announced, having achieved the restructuring of the Group's debt in 2012 and made significant progress in the development of the business, including key product launches, the Board concluded that it would be appropriate to appoint a Chief Financial Officer.
 
Listing Rule 9.6.13
 
In accordance with paragraph 9.6.13 of the Listing Rules, Skyepharma PLC confirms that Mr Derodra is currently a director of Tate & Lyle International Finance PLC and that there are no other disclosures to be made.

Suggested Articles

Researchers scoured the database where pharma companies disclose payments made to physicians and discovered a troubling trend.

Just a few months after playing a pivotal role in Sanofi’s Bioverativ buy, Alex Denner has set his sights on Ironwood.

Clovis' new approval will boost Rubraca in recurrent ovarian cancer, but because of its competitors' head start, the race will be tough.